Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism

Molecular Oncology

Volumn 8, Issue 1, 2014, Pages 27-38

  Gil Araujo, Beatriz ^a   Toledo Lobo, María Val ^b,c   Gutiérrez Salmerón, María ^a   Gutiérrez Pitalúa, Julia ^a   Ropero, Santiago ^b   Angulo, Javier C ^d   Chiloeches, Antonio ^b   Lasa, Marina ^a  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^d HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Apoptosis; Dual specificity phosphatase 1; NF B; P38 MAPK; Prostate cancer

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CONTROLLED STUDY; DNA CONTENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BENIGN PROSTATIC HYPERPLASIA; BPH; DUAL SPECIFICITY PHOSPHATASE 1; DUSP1; FITC; FLUORESCEIN ISOTHIOCYANATE; MAPK; MITOGEN-ACTIVATED PROTEIN KINASE; NF-ΚB; NUCLEAR FACTOR ΚB; P38 MAPK; PARP; PC; PI; PIN; POLY (ADP-RIBOSE) POLYMERASE; PROPIDIUM IODIDE; PROSTATE CANCER; PROSTATIC ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TETRAMETHYLRHODAMINE METHYL ESTER; TMRM; TNF-Α; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL LINE, TUMOR; DUAL SPECIFICITY PHOSPHATASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84892994083     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.08.012     Document Type: Article

References (48)

1. Baeza-Raja B., Munoz-Canoves P. p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol. Biol. Cell 2004, 15:2013-2026.
2. Boutros T., Chevet E., Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol. Rev. 2008, 60:261-310.
3. Calleros L., Lasa M., Toro M.J., Chiloeches A. Low cell cholesterol levels increase NFkappaB activity through a p38 MAPK-dependent mechanism. Cell. Signal. 2006, 18:2292-2301.
4. Curtin J.F., Cotter T.G. JNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells. J. Biol. Chem. 2004, 279:17090-17100.
5. Chattopadhyay S., Machado-Pinilla R., Manguan-Garcia C., Belda-Iniesta C., Moratilla C., Cejas P., Fresno-Vara J.A., de Castro-Carpeno J., Casado E., Nistal M., Gonzalez-Baron M., Perona R. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 2006, 25:3335-3345.
6. Chen W., Liu L., Luo Y., Odaka Y., Awate S., Zhou H., Shen T., Zheng S., Lu Y., Huang S. Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells. Cancer Prev. Res. (Phila) 2012, 5:778-787.
7. Chiloeches A., Sanchez-Pacheco A., Gil-Araujo B., Aranda A., Lasa M. Thyroid hormone-mediated activation of the ERK/Dual specificity phosphatase 1 pathway augments the apoptosis of GH4C1 cells by down-regulating nuclear factor-kappaB activity. Mol. Endocrinol. 2008, 22:2466-2480.
8. Chopra D.P., Menard R.E., Januszewski J., Mattingly R.R. TNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett. 2004, 203:145-154.
9. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
10. Ennis B.W., Fultz K.E., Smith K.A., Westwick J.K., Zhu D., Boluro-Ajayi M., Bilter G.K., Stein B. Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J. Pharmacol. Exp. Ther. 2005, 313:325-332.
11. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
12. Gan L., Wang J., Xu H., Yang X. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prost. 2011, 71:1158-1166.
13. Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J., Budunova I.V. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci. 2002, 115:141-151.
14. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA: Cancer J. Clin. 2008, 58:71-96.
15. Kammerer R., Buchner A., Palluch P., Pongratz T., Oboukhovskij K., Beyer W., Johansson A., Stepp H., Baumgartner R., Zimmermann W. Induction of immune mediators in glioma and prostate cancer cells by non-lethal photodynamic therapy. PloS One 2011, 6:e21834.
16. Kato T., Delhase M., Hoffmann A., Karin M. CK2 is a c-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Molecular Cell. 2003, 12:829-839.
17. Keyse S.M. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000, 12:186-192.
18. Keyse S.M. Protein phosphatases and cancer. Preface. Cancer Metastasis Rev. 2008, 27:121-122.
19. King E.M., Holden N.S., Gong W., Rider C.F., Newton R. Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. J. Biol. Chem. 2009, 284:26803-26815.
20. Kosaka Y., Calderhead D.M., Manning E.M., Hambor J.E., Black A., Geleziunas R., Marcu K.B., Noelle R.J. Activation and regulation of the IkappaB kinase in human B cells by CD40 signaling. Eur J Immunol 1999, 29:1353-1362.
21. Lang R., Hammer M., Mages J. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J. Immunol. 2006, 177:7497-7504.
22. Lasa M., Gil-Araujo B., Palafox M., Aranda A. Thyroid hormone antagonizes tumor necrosis factor-alpha signaling in pituitary cells through the induction of Dual specificity phosphatase 1. Mol. Endocrin. 2010, 24:412-422.
23. Liu Y.X., Wang J., Guo J., Wu J., Lieberman H.B., Yin Y. DUSP1 is controlled by p53 during the cellular response to oxidative stress. Mol. Cancer Res.: MCR 2008, 6:624-633.
24. Loda M., Capodieci P., Mishra R., Yao H., Corless C., Grigioni W., Wang Y., Magi-Galluzzi C., Stork P.J. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am. J. Pathol. 1996, 149:1553-1564.
25. Magi-Galluzzi C., Mishra R., Fiorentino M., Montironi R., Yao H., Capodieci P., Wishnow K., Kaplan I., Stork P.J., Loda M. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab. Invest. 1997, 76:37-51.
26. Mehta P.B., Robson C.N., Neal D.E., Leung H.Y. Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. Oncogene 2001, 20:5359-5365.
27. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J., Young D.B., Barbosa M., Mann M., Manning A., Rao A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 1997, 278:860-866.
28. Naugler W.E., Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr. Opin. Gen. Develop. 2008, 18:19-26.
29. Nunez C., Cansino J.R., Bethencourt F., Perez-Utrilla M., Fraile B., Martinez-Onsurbe P., Olmedilla G., Paniagua R., Royuela M. TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology 2008, 53:166-176.
30. Oeckinghaus A., Hayden M.S., Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nature Immun. 2011, 12:695-708.
31. Orlowski R.Z., Small G.W., Shi Y.Y. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J. Biol. Chem. 2002, 277:27864-27871.
32. Pervin S., Singh R., Freije W.A., Chaudhuri G. MKP-1-induced dephosphorylation of extracellular signal-regulated kinase is essential for triggering nitric oxide-induced apoptosis in human breast cancer cell lines: implications in breast cancer. Cancer Res. 2003, 63:8853-8860.
33. Rauhala H.E., Porkka K.P., Tolonen T.T., Martikainen P.M., Tammela T.L., Visakorpi T. Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int. J. Cancer 2005, 117:738-745.
34. Ricote M., Garcia-Tunon I., Fraile B., Fernandez C., Aller P., Paniagua R., Royuela M. P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells. Apoptosis: Int. J. Prog. Cell Death 2006, 11:1969-1975.
35. Rodriguez-Berriguete G., Fraile B., Paniagua R., Aller P., Royuela M. Expression of NF-kappaB-related proteins and their modulation during TNF-alpha-provoked apoptosis in prostate cancer cells. Prostate 2012, 72:40-50.
36. Royuela M., Rodriguez-Berriguete G., Fraile B., Paniagua R. TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Hist. Histopath. 2008, 23:1279-1290.
37. Shin D.Y., Kim G.Y., Lee J.H., Choi B.T., Yoo Y.H., Choi Y.H. Apoptosis induction of human prostate carcinoma DU145 cells by Diallyl Disulfide via modulation of JNK and PI3K/AKT signaling pathways. Int. Journal of Molecular Sciences 2012, 13:14158-14171.
38. Srikanth S., Franklin C.C., Duke R.C., Kraft R.S. Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 1999, 199:169-178.
39. Sun B., Zhang X., Yonz C., Cummings B.S. Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells. Biochem Pharmacol 2010, 79:1727-1735.
40. Vaarala M.H., Hirvikoski P., Kauppila S., Paavonen T.K. Identification of androgen-regulated genes in human prostate. Molecular Medicine Reports 2012, 6:466-472.
41. Vanden Berghe W., Plaisance S., Boone E., De Bosscher K., Schmitz M.L., Fiers W., Haegeman G. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 1998, 273:3285-3290.
42. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nature Reviews. Cancer 2009, 9:537-549.
43. Wang J., Yin D.P., Liu Y.X., Baer R., Yin Y. Dual specificity phosphatase 1/CL100 is a direct transcriptional target of E2F-1 in the apoptotic response to oxidative stress. Cancer Res 2007, 67:6737-6744.
44. Wang Z., Xu J., Zhou J.Y., Liu Y., Wu G.S. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res 2006, 66:8870-8877.
45. Woronicz J.D., Gao X., Cao Z., Rothe M., Goeddel D.V. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 1997, 278:866-869.
46. Wu W., Pew T., Zou M., Pang D., Conzen S.D. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005, 280:4117-4124.
47. Xiao D., Choi S., Johnson D.E., Vogel V.G., Johnson C.S., Trump D.L., Lee Y.J., Singh S.V. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene 2004, 23:5594-5606.
48. Yano O., Kanellopoulos J., Kieran M., Le Bail O., Israel A., Kourilsky P. Purification of KBF1, a common factor binding to both H-2 and beta 2-microglobulin enhancers. The EMBO Journal 1987, 6:3317-3324.